Holen Sie sich die Stockscreener-App
14.53
5.37%
0.74
Vorhandelsmarkt:
14.79
0.26
+1.79%
Schlusskurs vom Vortag:
$13.79
Offen:
$13.83
24-Stunden-Volumen:
288.35K
Relative Volume:
0.65
Marktkapitalisierung:
$394.06M
Einnahmen:
$157.75M
Nettoeinkommen (Verlust:
$-29.73M
KGV:
-12.53
EPS:
-1.16
Netto-Cashflow:
$-21.00M
1W Leistung:
+10.49%
1M Leistung:
+18.23%
6M Leistung:
-13.20%
1J Leistung:
-39.15%
1-Tages-Spanne:
$13.83
$14.62
1-Wochen-Bereich:
$12.78
$14.62
52-Wochen-Spanne:
$8.04
$25.88
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Firmenname
Arcturus Therapeutics Holdings Inc
Sektor
Branche
Telefon
(858) 900-2660
Adresse
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie ARCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
14.53 | 356.64M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-28 | Eingeleitet | BTIG Research | Buy |
| 2024-08-12 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-07-24 | Eingeleitet | William Blair | Outperform |
| 2023-05-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-11-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-11-02 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-01-31 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Fortgesetzt | Goldman | Neutral |
| 2021-06-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-17 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Eingeleitet | Wells Fargo | Overweight |
| 2020-12-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Herabstufung | ROTH Capital | Buy → Sell |
| 2020-12-08 | Bestätigt | B. Riley Securities | Buy |
| 2020-12-07 | Bestätigt | B. Riley Securities | Buy |
| 2020-10-26 | Eingeleitet | Barclays | Overweight |
| 2020-10-06 | Eingeleitet | Citigroup | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-30 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-16 | Eingeleitet | Raymond James | Outperform |
| 2020-07-13 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-09 | Herabstufung | WBB Securities | Buy → Hold |
| 2020-02-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-07 | Eingeleitet | Guggenheim | Buy |
| 2020-02-06 | Eingeleitet | Guggenheim | Buy |
| 2019-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-09-20 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
Arcturus Therapeutics Holdings Inc. Stock Analysis and ForecastFree Trading Strategy Suggestions - jammulinksnews.com
Is Arcturus Therapeutics Holdings Inc. a good long term investmentAccelerated investment success - Autocar Professional
What drives Arcturus Therapeutics Holdings Inc. stock priceExplosive trading growth - jammulinksnews.com
What analysts say about Arcturus Therapeutics Holdings Inc. stockFree Stock Selection - jammulinksnews.com
What makes Arcturus Therapeutics Holdings Inc. stock price move sharplyFree Access to Community - Newser
What drives PLUR stock priceRobust investment performance - jammulinksnews.com
Arcturus Therapeutics Stock Rises After Promising Mid-Stage Data for OTC Deficiency Treatment - MSN
Best Stocks for Aggressive Growth Pro Stock Market SignalsFree Consultation - jammulinksnews.com
What drives KSPI stock priceFree Stock Market Forecast Reports - jammulinksnews.com
RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion Funding - GlobeNewswire Inc.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $54.00 Consensus PT from Analysts - Defense World
Why Arcturus Therapeutics Holdings Inc. stock attracts strong analyst attentionHigh Potential Safe Trades - Newser
How Arcturus Therapeutics Holdings Inc. stock performs during market volatilityRisk Managed Trading Strategy - Newser
Trend Tracker for (ARCT) - news.stocktradersdaily.com
Arcturus Therapeutics (NASDAQ:ARCT) Downgraded by Wall Street Zen to “Sell” - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World
Expert Outlook: Arcturus Therapeutics Through The Eyes Of 5 Analysts - Nasdaq
Arcturus Therapeutics stock rises as Cantor Fitzgerald reiterates Overweight rating - Investing.com
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program - BioSpace
Arcturus Therapeutics stock rises on positive OTC deficiency trial data By Investing.com - Investing.com Australia
Arcturus reports positive phase 2 results for OTC deficiency therapy - Investing.com
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency - Yahoo Finance
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Bank of America Corp DE - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Analysts Offer Predictions for ARCT FY2026 Earnings - Defense World
Two Sigma Investments LP Increases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
(ARCT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Squarepoint Ops LLC Sells 22,752 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics Holdings Inc (ARCT) Is A Good Stock To Invest In - Stocksregister
Arcturus Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Transcript : Arcturus Therapeutics Holdings Inc.Shareholder/Analyst Call - marketscreener.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Position Increased by Ameriprise Financial Inc. - Defense World
Nuveen Asset Management LLC Sells 10,221 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
BNP Paribas Financial Markets Sells 13,093 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet - sharewise
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Purchased by Deutsche Bank AG - Defense World
Finanzdaten der Arcturus Therapeutics Holdings Inc-Aktie (ARCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):